InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,464.62
(
-0.16%
)
US TECH 100
19,220.00
(
-0.20%
)
Dow Jones
39,150.33
(
0.04%
)
Brent Oil
84.39
(
0.00%
)
Bitcoin
64,244.02
(
0.24%
)
Post# of 252302
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 833
Posts 119891
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: masterlongevity post# 81559

Tuesday, 07/28/2009 5:03:52 PM

Tuesday, July 28, 2009 5:03:52 PM

Post# of 252302
MS Drugs: 2Q09 US Market Share 
 
         Sales Market 
           $M  Share  
 Copaxone 438   38% 
 Avonex   366   32% 
 Rebif    198   17% 
 Tysabri  125   11% 
 Other     22    2% 
 =====  =====  ==== 
 Total  1,149  100%
Copaxone, Avonex, and Tysabri sales are as reported
by Teva and Biogen Idec; Rebif sales are estimated
from Merck KGaA and PFE financial statements.


“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up